Brendan Smith
Stock Analyst at TD Cowen
(1.99)
# 3,140
Out of 5,090 analysts
9
Total ratings
50%
Success rate
5.98%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Hold | $8 → $7 | $6.91 | +1.30% | 2 | Nov 4, 2025 | |
| WST West Pharmaceutical Services | Initiates: Buy | $350 | $280.23 | +24.90% | 1 | Oct 29, 2025 | |
| SLP Simulations Plus | Initiates: Hold | $16 | $19.64 | -18.53% | 1 | Sep 30, 2025 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $9.25 | +8.11% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $63.33 | +2.64% | 2 | Aug 7, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $61.44 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $19.96 | - | 1 | Dec 5, 2022 |
Novavax
Nov 4, 2025
Maintains: Hold
Price Target: $8 → $7
Current: $6.91
Upside: +1.30%
West Pharmaceutical Services
Oct 29, 2025
Initiates: Buy
Price Target: $350
Current: $280.23
Upside: +24.90%
Simulations Plus
Sep 30, 2025
Initiates: Hold
Price Target: $16
Current: $19.64
Upside: -18.53%
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $9.25
Upside: +8.11%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $63.33
Upside: +2.64%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $61.44
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $19.96
Upside: -